Fresenius Medical Care AG & Co. KGaA Sponsored ADR Forecast, price target & analysts
Why the stock moved Beta
Fresenius Medical Care AG & Co. KGaA Sponsored ADR Target price 2026 - Analyst rating & recommendation
Fresenius Medical Care AG & Co. KGaA Sponsored ADR Classifications & Recommendation
Fresenius Medical Care AG & Co. KGaA Sponsored ADR Price Target
| Target Price | $49.11 |
| Price | $22.07 |
| Potential |
122.51%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target Fresenius Medical Care AG & Co. KGaA Sponsored ADR 2027 .
The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR target price is $49.11.
This is
122.51%
register free of charge
$77.03
249.04%
register free of charge
$25.15
13.97%
register free of charge
|
|
| A rating was issued by 29 analysts: 6 Analysts recommend Fresenius Medical Care AG & Co. KGaA Sponsored ADR to buy, 11 to hold and 12 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fresenius Medical Care AG & Co. KGaA Sponsored ADR stock has an average upside potential 2027 of
122.51%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 22.52 | 22.48 |
| 1.51% | 0.07% | |
| EBITDA Margin | 16.64% | 18.05% |
| 6.95% | 8.48% | |
| Net Margin | 4.98% | 5.59% |
| 79.18% | 12.14% |
23 Analysts have issued a sales forecast Fresenius Medical Care AG & Co. KGaA Sponsored ADR 2026 . The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR sales estimate is
This results in the following potential growth metrics:
20 Analysts have issued an Fresenius Medical Care AG & Co. KGaA Sponsored ADR EBITDA forecast 2026. The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Fresenius Medical Care AG & Co. KGaA Sponsored ADR Analysts have issued a net profit forecast 2026. The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.86 | 4.72 |
| 83.81% | 22.60% | |
| P/E | 4.86 | |
| EV/Sales | 1.02 |
23 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast for earnings per share. The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Fresenius Medical Care AG & Co. KGaA Sponsored ADR...
Current Fresenius Medical Care AG & Co. KGaA Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| INTESA SANPAOLO EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| METZLER EQUITIES |
Locked
➜
Locked
|
Locked | Jun 18 2026 |
| BAADER EUROPE / ALPHAVALUE |
Locked
➜
Locked
|
Locked | Jun 17 2026 |
| TRUIST SECURITIES |
Locked
➜
Locked
|
Locked | May 20 2026 |
| LANDESBANK BADEN-WUERTTEMBERG |
Locked
➜
Locked
|
Locked | May 14 2026 |
| DZ BANK |
Locked
➜
Locked
|
Locked | May 10 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | May 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
INTESA SANPAOLO EQUITY RESEARCH:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
METZLER EQUITIES:
Locked
➜
Locked
|
Jun 18 2026 |
|
Locked
BAADER EUROPE / ALPHAVALUE:
Locked
➜
Locked
|
Jun 17 2026 |
|
Locked
TRUIST SECURITIES:
Locked
➜
Locked
|
May 20 2026 |
|
Locked
LANDESBANK BADEN-WUERTTEMBERG:
Locked
➜
Locked
|
May 14 2026 |
|
Locked
DZ BANK:
Locked
➜
Locked
|
May 10 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
May 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
